Last updated: February 28, 2026
Case Overview
Bayer Schering Pharma AG filed a patent infringement suit against Lupin Ltd. in the U.S. District Court for the Southern District of New York. The case number is 1:10-cv-05423. Bayer alleged that Lupin’s generic version of its oral contraceptive, Yasmin, infringed multiple patents related to the drug's formulation and method of use. The litigation focused on the validity, enforceability, and infringement of Bayer’s patents—primarily U.S. Patent Nos. 7,617,060 and 7,878,947.
Patent Details
- Patent 7,617,060: Covers a pharmaceutical composition comprising drospirenone and ethinylestradiol in specific ratios, with claims directed to the drug's formulation and its method of manufacture.
- Patent 7,878,947: Claims methods of preparing drospirenone-containing tablets with particular release profiles.
Legal Claims
Bayer argued that Lupin’s generic products infringe on the patents through the manufacture and sale of their drospirenone-containing oral contraceptives. Bayer maintained that the patents were valid and enforceable and that Lupin’s products fell within the scope of the patent claims. Lupin countered with defenses including patent invalidity based on obviousness, lack of infringement, and inequitable conduct during patent prosecution.
Key Events
- Initial Filing: Bayer filed suit on August 16, 2010, seeking preliminary and permanent injunctions, damages, and declaratory judgments of patent validity.
- Lupin’s Response: Lupin filed a motion to dismiss and later a counterclaim for patent invalidity.
- Discovery & Patent Interplay: Discovery revealed technical details about formulation, manufacturing processes, and prior art references.
- Summary Judgment Motions: Both parties filed motions for summary judgment on issues of infringement and validity.
- Trial & Decision: The case was settled before a bench trial, with Bayer obtaining preliminary injunctive relief and Lupin agreeing to delay launch pending resolution.
Settlement & Outcomes
In 2012, Bayer and Lupin settled the litigation confidentially. The settlement included a license agreement allowing Lupin to market its generic drospirenone-ethinylestradiol product after certain patent expiration dates. The terms specified delays in launch and royalties payable to Bayer.
Legal Significance
This case underscores the importance of patent-based exclusivity in the oral contraceptive market. The litigation highlighted issues surrounding patent validity challenges based on obviousness and prior art. It also exemplifies strategic patent litigation practices, including settlement agreements that delay generic entry.
Lessons for Industry
- Patent claims related to formulation and manufacturing processes remain critical and contestable.
- Patent validity challenges often involve technical prior art comparisons to defend against generic infringing products.
- Settlement agreements remain common to manage market entry timelines and royalty terms.
Key Takeaways
- Bayer litigated patent rights against Lupin’s generic Yasmin, focusing on formulation and manufacturing patents.
- The case was settled with Lupin obtaining a license to market its product after patent expiration, avoiding a trial.
- Patent validity, enforceability, and infringement are core issues in pharmaceutical patent litigations.
- Confidential settlements are frequent in pharmaceutical patent disputes to control market entry timelines.
- Litigation outcomes influence generic drug market strategies, emphasizing the value of patent prosecution and defenses.
FAQs
1. What patents were at the center of Bayer’s litigation against Lupin?
The case mainly involved U.S. Patent Nos. 7,617,060 and 7,878,947, covering formulation ratios and manufacturing methods for drospirenone oral contraceptives.
2. How did the case affect the timing of Lupin’s product launch?
The settlement delayed Lupin’s market entry, with terms allowing launch after patent expiry and including royalty payments.
3. What legal defenses did Lupin assert?
Lupin argued patent invalidity based on obviousness and prior art, as well as non-infringement and issues related to patent prosecution misconduct.
4. Did the court issue a final ruling on patent validity or infringement?
No. The case settled before a final court ruling, with the resolution including licensing terms rather than a court determination on patent validity.
5. Why are patent disputes like this critical in the pharmaceutical industry?
They determine the exclusivity period for innovative drugs, impacting market share, pricing, and generic competition strategies.
References
[1] Bayer Schering Pharma AG v. Lupin Ltd., 1:10-cv-05423, U.S. District Court for the Southern District of New York (2010).
[2] U.S. Patent No. 7,617,060.
[3] U.S. Patent No. 7,878,947.
